01 / Customer question
The commercial context
Evidence, audience and intended use change the requirements.
Provider discovery, patient education, professional medical information and clinical systems serve different purposes. The evidence and controls required for one should not be assumed to suit the others. Audience, market and intended use shape the assessment.
Outdated evidence, unsupported indications and omitted limitations can materially change the meaning of an answer. We assess public representation against approved information with the appropriate specialists. Private knowledge and administrative use cases are considered separately, with permissions and review defined before a pilot.
Customer journeys
Assess patient, professional and scientific journeys separately.
We agree the questions, audiences and markets to assess. The examples below show what we can investigate, with the final scope based on your priorities.
02 / Customer question
Does a treatment/device explanation preserve indications, evidence dates and material limitations?
03 / Customer question
Can an authorised professional retrieve the correct scientific or medical reference with traceable evidence?
01
Discovery and representation
We scope provider, therapeutic-area or device journeys for the selected audience and market. The findings identify representation gaps without treating patient and professional questions as interchangeable.
You receive: Representation baseline and audience-specific gaps.
02
Evidence and approved-content evaluation
We compare material claims with approved information and specialist-reviewed evidence. The assessment records reference dates, applicability and limitations, and identifies information needing an update or further qualified review.
You receive: Evidence/claims map, error register and update priorities.
03
Private workflow readiness
We assess medical, scientific or administrative knowledge for permissioned assistance. The plan identifies data lineage, reviewer roles and a suitable task scope, with clinical or regulated validation requirements handled separately.
You receive: Knowledge architecture, evaluation scope and adoption roadmap.
Internal AI readiness
Prepare knowledge workflows for appropriate specialist oversight.
Patient and HCP access, medical or regulatory approval and quality processes need named owners. We assess the knowledge, records and workflow changes required for the intended task, preserving the boundary between retrieval, assistance and a clinical decision.
Rights-cleared scientific information may support a separate licensing discussion. Patient records are not a generic monetisation asset. Pilots need traceable evidence, appropriate review and escalation; production clinical systems require additional specialist scope and validation beyond general consulting.
A practical first engagement
Health AI Information & Readiness Assessment
We choose a provider, pharmaceutical, biotechnology or device track, then agree the market, audience, services or products and approved references. You receive material-quality findings, evidence and access gaps, specialist dependencies and a prioritised roadmap for information changes or suitable workflow pilots.
01
Agree the scope
We agree the business questions, reference sources, AI platforms and teams involved. Before the assessment begins, we confirm the access needed and any work it depends on.
02
Review the evidence together
We separate what the AI answer shows from the content, data or workflow issues behind it. Your teams help decide which changes matter and which are feasible.
03
Choose the next action
The plan identifies the priorities, who is responsible, what each change depends on and how it will be checked. If a pilot is worthwhile, we agree how to run and evaluate it with the teams involved.
Evaluation
Measure the changes that matter.
We agree how to evaluate results before making changes. Each answer is recorded with its question, market, AI platform and date. Repeat checks help identify patterns. We assess commercial results and improvements to internal workflows separately with your teams.
Material claim accuracy
Evidence traceability
Audience and access correctness
Reviewed task quality
Part of Ayima
Technical search expertise. Practical enterprise thinking.
SWLR combines AI visibility and readiness consulting with Ayima's experience in enterprise search. We investigate the content, data and technical issues behind your business question, including access permissions, then help your teams decide what to do next.
Common questions
Before we begin.
Does this include clinical decision tools?
Clinical decision use is a distinct scope requiring the appropriate qualified specialists, intended-use assessment and validation. Public information or administrative assistance can be assessed separately. We define those boundaries before recommending a pilot.
Can we evaluate public AI without sharing patient data?
Yes. Approved public information and agreed references can support a representation assessment without patient records. Private use cases need separately agreed purpose, permissions, reviewers and data handling.
How do you handle conflicting or outdated evidence?
We record reference dates and evidence provenance, identify contradictions and refer material questions to qualified reviewers. The assessment distinguishes an unsupported claim from information that cannot be verified within the available references.
Signal → Evidence → Action
Start with the questions that matter.
Discuss the audience, services or products and specialist reviewers relevant to your assessment.
Discuss your AI strategy